NeuroSkye Therapeutics provides validated, iPSC-derived human BBB assembloids that deliver high-throughput, mechanism-based permeability data for CNS drug discovery. Their standardized assays reveal how and why molecules cross the blood-brain barrier, supporting confident go/no-go decisions and regulatory-ready NAM workflows. Every study is executed by the company's expert scientific team to ensure reproducibility and data reliability.
Funding
Funding not disclosed
Founders
Product
Problem
Central nervous system (CNS) drug development is hindered by the lack of human-relevant models that accurately predict blood-brain barrier (BBB) permeability and mechanism. Traditional in vitro and animal models often fail to translate to clinical outcomes, leading to costly late-stage failures and slowing the delivery of new therapies.
Solution
NeuroSkye Therapeutics delivers high-throughput, iPSC-derived BBB assembloids that combine 10+ years of published academic research with standardized, reproducible workflows. These human assembloids provide mechanistically predictive data that go beyond simple permeability scoring, revealing not just whether a molecule crosses the BBB but how and why it succeeds or fails. The platform supports a range of therapeutic areas including CNS, oncology, and neuroinflammation, and aligns with evolving FDA and global regulatory expectations for New Approach Methodologies (NAMs). All studies are performed exclusively by NeuroSkye's expert scientific team, ensuring rigorous quality control, assay reproducibility, and high-confidence data for drug development decisions.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing CNS therapeutics, as well as research organizations seeking human-relevant BBB permeability data for drug discovery and regulatory submissions.
Features
- iPSC-derived human BBB assembloids that replicate neurovascular physiology with high human relevance
- High-throughput, modular assay formats adaptable to diverse therapeutic areas and drug modalities
- Mechanistic readouts that distinguish passive permeability, efflux transport, and receptor-mediated transcytosis
- Rigorous standardization with published academic validation and robust quality control protocols
- NAM-compliant workflows designed to support global regulatory submissions and reduce reliance on animal models
- End-to-end study execution by an in-house expert scientific team, ensuring consistency and data reliability